Biotech News

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.2026-06-26 12:45 ESTClinical readout

MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal cancers unresponsive to checkpoint inhibitors Enrolment in ABILITY-1 to be

Open original release

Related news

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Announces the Finalization of the Terms of its Public Offering of Securities

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Announces the Launch of a Marketed Public Offering of Securities

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Updates MDNA11 Clinical Trial Results at the ESMO-IO Congress 2025, Further Bolstering its Anti-Tumor Activity in Advanced Solid Tumors

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Therapeutics Announces Key Program Updates and 2026 Outlook

MDNAMedicenna Therapeutics Corp.2026-06-25 13:46 EST

Medicenna Announces Changes to Board Composition

View all latest news

Medicenna Therapeutics Corp.

Medicenna Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

MDNAZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

MDNAZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

MDNABMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

MDNAGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

MDNAMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 0.16 USD
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States